Choi J - Search Results

1

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer.

Sampson J, Ju HM, Zhang N, Yeoh S, Choi J, Bayliss R. Sampson J, et al. Among authors: choi j. Cell Death Dis. 2024 Dec 18;15(12):912. doi: 10.1038/s41419-024-07272-7. Cell Death Dis. 2024. PMID: 39695132 Free PMC article.

2

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Bayliss R, et al. Among authors: choi j. Cell Mol Life Sci. 2016 Mar;73(6):1209-24. doi: 10.1007/s00018-015-2117-6. Epub 2016 Jan 11. Cell Mol Life Sci. 2016. PMID: 26755435 Free PMC article. Review.

3

EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.

O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA, Choi J, Bayliss R, Fry AM. O'Regan L, et al. Among authors: choi j. J Cell Sci. 2020 May 11;133(9):jcs241505. doi: 10.1242/jcs.241505. J Cell Sci. 2020. PMID: 32184261 Free PMC article.

4

Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.

Sampson J, Richards MW, Choi J, Fry AM, Bayliss R. Sampson J, et al. Among authors: choi j. EMBO Rep. 2021 Dec 6;22(12):e53693. doi: 10.15252/embr.202153693. Epub 2021 Oct 18. EMBO Rep. 2021. PMID: 34661367 Free PMC article.

5

EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.

Lucken K, O'Regan L, Choi J, Sampson J, Pashley SL, Bayliss R, Khan S, Fry AM. Lucken K, et al. Among authors: choi j. Mol Cancer Res. 2022 Jun 3;20(6):854-866. doi: 10.1158/1541-7786.MCR-21-1010. Mol Cancer Res. 2022. PMID: 35656694 Free PMC article.

6

HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors.

Kim M, Ju HM, Song JY, Sampson J, Bayliss R, Choi J. Kim M, et al. Among authors: choi j. Transl Lung Cancer Res. 2024 Feb 29;13(2):321-333. doi: 10.21037/tlcr-23-804. Epub 2024 Feb 28. Transl Lung Cancer Res. 2024. PMID: 38496685 Free PMC article.

7

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC.

Sampson J, Ju HM, Song JY, Fry AM, Bayliss R, Choi J. Sampson J, et al. Among authors: choi j. Cancers (Basel). 2022 Feb 2;14(3):779. doi: 10.3390/cancers14030779. Cancers (Basel). 2022. PMID: 35159046 Free PMC article.

8

Overexpression of the NEK9-EG5 axis is a novel metastatic marker in pathologic stage T3 colon cancer.

Kim M, Jeong HJ, Ju HM, Song JY, Jang SJ, Choi J. Kim M, et al. Among authors: choi j. Sci Rep. 2023 Jan 7;13(1):342. doi: 10.1038/s41598-022-26249-0. Sci Rep. 2023. PMID: 36611072 Free PMC article.

9

Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.

Lee Y, Park S, Kim WS, Lee JC, Jang SJ, Choi J, Choi CM. Lee Y, et al. Among authors: choi j, choi cm. Thorac Cancer. 2018 Sep;9(9):1104-1110. doi: 10.1111/1759-7714.12793. Epub 2018 Jul 10. Thorac Cancer. 2018. PMID: 29989342 Free PMC article.

10

Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.

Chun SM, Lee JY, Choi J, Lee JH, Hwang JJ, Kim CS, Suh YA, Jang SJ. Chun SM, et al. Among authors: choi j. PLoS One. 2015 Mar 17;10(3):e0119379. doi: 10.1371/journal.pone.0119379. eCollection 2015. PLoS One. 2015. PMID: 25781604 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35,105 results

Search Page

Filters